Patients First at PoP we believe that by putting the Patient First we make Better Drugs
More targeted drugs for pancreatic cancer and infectious diseases mean less side effects and better clinical outcomes for these patients in dire need of new treatment options. PoP has identified multiple unique modes of action that are being developed to tackle these diseases.
Unlocking Chemical Dark Matter from Untapped Natural Resources PoP has created a platform technology which facilitates the discovery of novel therapeutic compounds from extreme environments, such as the hot springs of Yellowstone National Park.
The EDeN platform utilizes synthetic biology to discover bioactive molecules.
Developing Innovative Therapies for:
Pancreatic Cancer
Multi-Drug Resistant Infections
COVID-19
Emerging Viral Infections
Atopic Dermatitis
PIPELINE SBIR Grants have been awarded to all 6 of our drug programs
Team
PoP is located on the HudsonAlpha Institute campus which facilitates biotech collaborations.